A venture capital firm based in Europe is solely focused on life sciences. The firm had a recent close on their fourth fund and is actively looking for new investments, usually in Series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America with more of a focus on the U.S.
The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is not evaluating diagnostic technologies for the current fund. The firm is generally agnostic in terms of subsectors and indications with the primary focus on products that address clear unmet opportunities. Historically, the firm has invested in biotech therapeutics that address a wide variety of inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases.
The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment